Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 281

1.

Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.

Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C.

J Clin Virol. 2013 Sep;58(1):161-7. doi: 10.1016/j.jcv.2013.06.041. Epub 2013 Jul 27.

PMID:
23895930
2.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969
3.

Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.

Jentschke M, Soergel P, Hillemanns P.

J Virol Methods. 2013 Oct;193(1):131-4. doi: 10.1016/j.jviromet.2013.05.009. Epub 2013 May 23.

PMID:
23707925
4.

Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.

Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C.

J Virol Methods. 2009 Mar;156(1-2):77-83. doi: 10.1016/j.jviromet.2008.11.002. Epub 2008 Dec 17.

PMID:
19041893
5.

Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women.

Ngou J, Gilham C, Omar T, Goumbri-Lompo O, Doutre S, Michelow P, Kelly H, Didelot MN, Chikandiwa A, Sawadogo B, Delany-Moretlwe S, Meda N, Costes V, Mayaud P, Segondy M.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):162-8. doi: 10.1097/QAI.0000000000000428.

PMID:
25394189
6.

Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes.

Lindemann ML, Dominguez MJ, de Antonio JC, Sandri MT, Tricca A, Sideri M, Khiri H, Ravet S, Boyle S, Aldrich C, Halfon P.

J Mol Diagn. 2012 Jan;14(1):65-70. doi: 10.1016/j.jmoldx.2011.09.005. Epub 2011 Nov 10.

PMID:
22079749
7.

Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.

Gillio-Tos A, De Marco L, Carozzi FM, Del Mistro A, Girlando S, Burroni E, Frayle-Salamanca H, Giorgi Rossi P, Pierotti P, Ronco G; New Technologies for Cervical Cancer Screening Working Group..

J Clin Microbiol. 2013 Sep;51(9):2901-7. doi: 10.1128/JCM.01047-13. Epub 2013 Jun 26.

8.

Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.

Huang S, Erickson B, Tang N, Mak WB, Salituro J, Robinson J, Abravaya K.

J Clin Virol. 2009 Jul;45 Suppl 1:S19-23. doi: 10.1016/S1386-6532(09)70004-6.

PMID:
19651364
9.

Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.

Yu S, Kwon MJ, Lee EH, Park H, Woo HY.

J Med Virol. 2015 Sep;87(9):1587-93. doi: 10.1002/jmv.24206. Epub 2015 Apr 24.

PMID:
25914215
10.

An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.

Thai H, Rangwala S, Gay T, Keating K, McLeod S, Nazarenko I, O'Neil D, Pfister D, Loeffert D.

J Clin Virol. 2009 Jul;45 Suppl 1:S93-7. doi: 10.1016/S1386-6532(09)70014-9.

PMID:
19651375
11.

Clinical performance characteristics of the Cervista HPV HR test kit in cervical cancer screening in China.

Zhao J, Zhang X, Ma J, Liu G, Yao D, Zhang W, Wang J, Wei L, Zhao Y, Zeng Y, Liao Q.

J Low Genit Tract Dis. 2012 Oct;16(4):358-63.

PMID:
23023138
12.
14.

Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests.

Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, Kinney W, Fetterman B, Lorey T, Schiffman M, Castle PE; PaP Cohort Study Group..

J Clin Microbiol. 2012 Jan;50(1):61-5. doi: 10.1128/JCM.05989-11. Epub 2011 Nov 9.

15.

A weakly positive human papillomavirus Hybrid Capture II result correlates with a significantly lower risk of cervical intraepithelial neoplasia 2,3 after atypical squamous cells of undetermined significance cytology.

Jarboe EA, Venkat P, Hirsch MS, Cibas ES, Crum CP, Garner EI.

J Low Genit Tract Dis. 2010 Jul;14(3):174-8. doi: 10.1097/LGT.0b013e3181cd6d4b.

PMID:
20592551
16.

Development and characterization of the cobas human papillomavirus test.

Rao A, Young S, Erlich H, Boyle S, Krevolin M, Sun R, Apple R, Behrens C.

J Clin Microbiol. 2013 May;51(5):1478-84. doi: 10.1128/JCM.03386-12. Epub 2013 Feb 27.

17.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
18.

Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix.

Lapierre SG, Sauthier P, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, Franco EL, Coutlée F.

J Clin Microbiol. 2012 Apr;50(4):1240-4. doi: 10.1128/JCM.06656-11. Epub 2012 Feb 1.

19.

Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping.

Seme K, Fujs K, Kocjan BJ, Poljak M.

J Virol Methods. 2006 Jun;134(1-2):252-6. Epub 2006 Jan 18.

PMID:
16417931
20.

Supplemental Content

Support Center